Intero Biosystems

Intero Biosystems is a biotechnology firm focused on developing organoid technology, particularly through its product GastroScreen, aimed at enhancing drug testing methodologies for pharmaceutical and research entities. Intero Biosystems was founded in 2024 in Michigan City, US, and specializes in organoid technology. The firm has executed 1 deal to date, with the most recent deal occurring on March 1, 2025. The company was founded by individuals with a background in biotechnology, although specific names are not provided.

Intero Biosystems specializes in the development of innovative organoid technology, centering on its flagship product, GastroScreen. This product features a stem-cell-derived miniature model of the human intestine, mirroring essential components such as neurons, blood vessels, muscle, and the inner intestinal lining. This model facilitates preclinical drug testing for pharmaceutical firms, research institutions, and biotech companies, aiming to minimize risks and costs during drug development. The company serves a broad global clientele in North America, Europe, and Asia, responding to the rising demand for advanced drug testing solutions.

Intero Biosystems generates revenue through B2B transactions, primarily from partnerships with pharmaceutical companies and research institutions interested in its organoid technology for preclinical testing. Client agreements typically involve subscription-based access or one-time purchase arrangements for specific research endeavors, with pricing tailored to the testing services required. The firm positions its products as vital resources for drug development, fostering long-term client relationships that contribute to its revenue streams. Intero Biosystems plans to enhance its product line with new innovations in organoid technology, targeting the launch of additional organoid models by late 2025.

The company aims to expand its market presence into Asia and Europe within the next year, intending to establish new partnerships with local pharmaceutical firms. The recent pre-seed funding raised in March 2025 from Michigan Rise will support these initiatives, enabling the development of new products and the expansion into targeted markets.